CN1724014A - 威灵仙总皂苷提取物、其制备方法及其在制备药物中的用途 - Google Patents
威灵仙总皂苷提取物、其制备方法及其在制备药物中的用途 Download PDFInfo
- Publication number
- CN1724014A CN1724014A CN 200510040824 CN200510040824A CN1724014A CN 1724014 A CN1724014 A CN 1724014A CN 200510040824 CN200510040824 CN 200510040824 CN 200510040824 A CN200510040824 A CN 200510040824A CN 1724014 A CN1724014 A CN 1724014A
- Authority
- CN
- China
- Prior art keywords
- extractive
- total saponin
- clematis root
- group
- clematis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229930182490 saponin Natural products 0.000 title claims abstract description 30
- 150000007949 saponins Chemical class 0.000 title claims abstract description 30
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims abstract description 28
- 241000218158 Clematis Species 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 41
- 206010061218 Inflammation Diseases 0.000 claims abstract description 14
- 239000011347 resin Substances 0.000 claims abstract description 14
- 229920005989 resin Polymers 0.000 claims abstract description 14
- 238000010992 reflux Methods 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 39
- 241000903946 Clematidis Species 0.000 claims description 29
- 150000002338 glycosides Chemical class 0.000 claims description 24
- 229930182470 glycoside Natural products 0.000 claims description 23
- 230000004054 inflammatory process Effects 0.000 claims description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 10
- 238000010828 elution Methods 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 229910021529 ammonia Inorganic materials 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 241001256368 Clematis chinensis Species 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000003513 alkali Substances 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 abstract description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 38
- 229960003957 dexamethasone Drugs 0.000 description 30
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 30
- 241001465754 Metazoa Species 0.000 description 29
- 241000700159 Rattus Species 0.000 description 28
- 210000001541 thymus gland Anatomy 0.000 description 27
- 210000000952 spleen Anatomy 0.000 description 23
- 230000037396 body weight Effects 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- 230000008961 swelling Effects 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 18
- 235000017709 saponins Nutrition 0.000 description 18
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 17
- 239000000843 powder Substances 0.000 description 15
- 208000009386 Experimental Arthritis Diseases 0.000 description 14
- 210000002683 foot Anatomy 0.000 description 14
- 239000002671 adjuvant Substances 0.000 description 12
- 229960001138 acetylsalicylic acid Drugs 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 238000011552 rat model Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102000019197 Superoxide Dismutase Human genes 0.000 description 7
- 108010012715 Superoxide dismutase Proteins 0.000 description 7
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 6
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 6
- 229960002246 beta-d-glucopyranose Drugs 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 4
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 4
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 210000003060 endolymph Anatomy 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 229940100243 oleanolic acid Drugs 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000002992 thymic effect Effects 0.000 description 4
- NTWLPZMPTFQYQI-UHFFFAOYSA-N (3alpha)-olean-12-ene-3,23-diol Natural products C1CC(O)C(C)(CO)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC3C21C NTWLPZMPTFQYQI-UHFFFAOYSA-N 0.000 description 3
- GCGBHJLBFAPRDB-UHFFFAOYSA-N Hederagenin Natural products CC1(C)CCC2(CCC3(C)C4CCC5C(C)(CO)C(O)CCC5(C)C4CC=C3C2C1)C(=O)O GCGBHJLBFAPRDB-UHFFFAOYSA-N 0.000 description 3
- GCGBHJLBFAPRDB-KCVAUKQGSA-N Scutellaric acid Natural products CC1(C)CC[C@@]2(CC[C@@]3(C)[C@@H]4CC[C@H]5[C@@](C)(CO)[C@H](O)CC[C@]5(C)[C@H]4CC=C3[C@@H]2C1)C(=O)O GCGBHJLBFAPRDB-KCVAUKQGSA-N 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003194 forelimb Anatomy 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- -1 glycosyl oleanolicacid Chemical compound 0.000 description 3
- PGOYMURMZNDHNS-MYPRUECHSA-N hederagenin Chemical compound C1C[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C PGOYMURMZNDHNS-MYPRUECHSA-N 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 229930182495 oleanane-type triterpene Natural products 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 230000008925 spontaneous activity Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- JAJIPIAHCFBEPI-UHFFFAOYSA-N 9,10-dioxoanthracene-1-sulfonic acid Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2S(=O)(=O)O JAJIPIAHCFBEPI-UHFFFAOYSA-N 0.000 description 1
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 241000725146 Clematis hexapetala Species 0.000 description 1
- 241000915582 Clematis manshurica Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940085421 aspirin 500 mg Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940082484 carbomer-934 Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000003108 foot joint Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940054136 kineret Drugs 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
剂量(g/kg) | 对数剂量 | 动物数(只) | 逐日死亡情况1d 2-14d | 死亡数(只) | 死亡率(%) | 实验机率单位 | LD50(g/kg) | 95%可信限(g/kg) |
1.4341.0750.8060.6050.454 | 0.160.03-0.09-0.22-0.34 | 1010101010 | 108530 | 00000 | 108530 | 1008050300 | 6.965.845.004.483.04 | 0.78 | 0.67~0.91 |
剂量(g/kg) | 对数剂量 | 动物数(只) | 逐日死亡情况1d 2-14d | 死亡数(只) | 死亡率(%) | 实验机率单位 | LD50(g/kg) | 95%可信限(g/kg) |
1.2460.9340.7000.5250.394 | 0.10-0.03-0.15-0.28-0.40 | 1010101010 | 10 07 05 02 00 0 | 107520 | 1007050200 | 6.965.525.004.163.04 | 0.72 | 0.62~0.84 |
药物 | 批号 | 剂量 | 总皂苷含量 | 有效部位 |
1号2号 | 041020041021 | 0.047g浸膏=1g药材0.165g浸膏=1g药材 | 63.00%4.99% | 有效部位非有效部位 |
组别 | 剂量(mg浸膏粉/kg) | 肿胀率(%) | 抑制率(%) |
1高1低2高2低地塞米松阿司匹林模型对照 | 56.428.2198.099.00.4500.0 | 10.54±7.62*12.65±5.44*13.23±11.6818.26±14.0710.07±6.00**11.61±2.17*22.38±12.12 | 52.9343.4940.9018.4155.0248.13 |
组别 | 剂量(mg浸膏粉 | 体重(g) | 胸腺(g/100g体重) | 脾(g/100g体重) |
1高1低2高2低地塞米松阿司匹林模型对照 | 56.428.2198.099.00.4500.0 | 201.1±11.20**206.2±15.90**200.4±21.48**204.7±20.49**155±9.20203.6±12.49**194.8±0.80** | 0.162±0.021**0.165±0.015**0.168±0.021**0.169±0.019**0.063±0.0320.174±0.072**0.192±0.10** | 1.108±0.126**1.135±0.166**1.234±0.250**1.061±0.100**0.401±0.0760.935±0.136**1.257±0.308** |
组别 | 剂量(mg浸膏粉/kg) | 肿胀率(%) | 抑制率(%) |
高1低1高2低2地塞米松阿司匹林模型对照 | 56.428.2198.099.00.4mg/kg500 | 4.62±5.42**10.72±9.24**10.34±9.54**11.65±10.36*3.06±2.53**5.12±4.35**25.64±27.34 | 83.1160.7762.1857.37186.1281.28 |
组别 | 剂量(mg浸膏粉/kg) | 体重(g) | 胸腺(g/100g体重) | 脾(g/100g体重) |
高1低1高2低2地塞米松阿司匹林模型对照 | 56.428.2198990.4500.0 | 262.100±18.36**263.600±27.14**276.400±32.11**278.100±35.10**219.100±25.96283.200±28.13**279.500±35.05** | 0.164±0.031**0.163±0.047**0.149±0.049**0.145±0.057**0.065±0.0120.155±0.015**0.249±0.066** | 0.822±0.122**0.702±0.217**0.556±0.148**0.815±0.145**0.253±0.0470.727±0.113**1.022±0.253** |
组别 | 剂量(mg浸膏粉/kg) | MDA(U/L) | SOD(U/L) |
高1低1高2低2地塞米松阿司匹林模型对照 | 56.428.2198.099.00.4mg/kg500.0 | 0.160±0.055**0.168±0.065**0.186±0.057*0.196±0.053*0.143±0.052**0.145±0.061**0.238±0.034 | 115.287±4.937**118.265±4.706**119.425±2.700**120.929±1.979**113.579±4.102**119.566±1.489**107.670±3.179 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100408242A CN1330328C (zh) | 2005-06-29 | 2005-06-29 | 威灵仙总皂苷提取物、其制备方法及其在制备药物中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100408242A CN1330328C (zh) | 2005-06-29 | 2005-06-29 | 威灵仙总皂苷提取物、其制备方法及其在制备药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1724014A true CN1724014A (zh) | 2006-01-25 |
CN1330328C CN1330328C (zh) | 2007-08-08 |
Family
ID=35923732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100408242A Expired - Fee Related CN1330328C (zh) | 2005-06-29 | 2005-06-29 | 威灵仙总皂苷提取物、其制备方法及其在制备药物中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1330328C (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102120778A (zh) * | 2010-12-20 | 2011-07-13 | 大兴安岭嘉迪欧营养原料有限公司 | 一种富集纯化铁线莲中铁线莲皂苷的方法 |
CN102327335A (zh) * | 2011-07-26 | 2012-01-25 | 苏州宝泽堂医药科技有限公司 | 一种从威灵仙中提取总皂苷的方法 |
CN102488764A (zh) * | 2011-12-29 | 2012-06-13 | 中国人民解放军第三军医大学第一附属医院 | 茅莓总皂苷的制备方法 |
CN102603763A (zh) * | 2012-02-20 | 2012-07-25 | 中山大学 | 一种从威灵仙中提取木脂素类化合物的方法及应用 |
CN103655769A (zh) * | 2012-09-12 | 2014-03-26 | 江西本草天工科技有限责任公司 | 东北铁线莲皂苷提取物的制备及其抗肿瘤应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1193775C (zh) * | 2000-12-30 | 2005-03-23 | 李毅 | 治疗类风湿性关节炎、强直性脊柱炎的类风湿药 |
-
2005
- 2005-06-29 CN CNB2005100408242A patent/CN1330328C/zh not_active Expired - Fee Related
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102120778A (zh) * | 2010-12-20 | 2011-07-13 | 大兴安岭嘉迪欧营养原料有限公司 | 一种富集纯化铁线莲中铁线莲皂苷的方法 |
CN102120778B (zh) * | 2010-12-20 | 2014-04-02 | 大兴安岭嘉迪欧营养原料有限公司 | 一种富集纯化铁线莲中铁线莲皂苷的方法 |
CN102327335A (zh) * | 2011-07-26 | 2012-01-25 | 苏州宝泽堂医药科技有限公司 | 一种从威灵仙中提取总皂苷的方法 |
CN102488764A (zh) * | 2011-12-29 | 2012-06-13 | 中国人民解放军第三军医大学第一附属医院 | 茅莓总皂苷的制备方法 |
CN102488764B (zh) * | 2011-12-29 | 2013-10-16 | 中国人民解放军第三军医大学第一附属医院 | 茅莓总皂苷的制备方法 |
CN102603763A (zh) * | 2012-02-20 | 2012-07-25 | 中山大学 | 一种从威灵仙中提取木脂素类化合物的方法及应用 |
CN103655769A (zh) * | 2012-09-12 | 2014-03-26 | 江西本草天工科技有限责任公司 | 东北铁线莲皂苷提取物的制备及其抗肿瘤应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1330328C (zh) | 2007-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1684699A (zh) | 从忍冬茎中提取和纯化活性成分的方法、其在抗炎和止痛药中的应用 | |
CN1836725A (zh) | 一种治疗关节炎的中药组合物及其制备方法 | |
CN1300176C (zh) | 一种新皂苷及其衍生物、其制备方法及其医药用途 | |
CN1931228A (zh) | 金钱草总黄酮提取物及其制备方法 | |
CN1698858A (zh) | 一种治疗急性痛风的药物组合物及其提取方法 | |
CN1330328C (zh) | 威灵仙总皂苷提取物、其制备方法及其在制备药物中的用途 | |
CN1887323A (zh) | 一种中药组合物及其制备方法和质量控制方法 | |
CN1141101C (zh) | 治疗乙肝的药物及其制备方法 | |
CN101040891A (zh) | 昆明山海棠生物碱制备方法及其应用 | |
CN1130212C (zh) | 治疗痞症的药物及其制备方法 | |
CN1887316A (zh) | 一种中药组合物及其制备方法和应用 | |
CN1312077A (zh) | 甘草和苦参有效提取物组成的复方组份及其应用 | |
CN1857492A (zh) | 清泻制剂及新的制备方法 | |
CN1270755C (zh) | 一种治疗风湿类风湿性关节炎的药物组合物 | |
CN1301544A (zh) | 治疗关节炎及骨关节病的药物组合物及其制备方法 | |
CN1203891C (zh) | 治疗冠心病的药物及制备方法 | |
CN1265806C (zh) | 治疗风湿病的药物组合物 | |
CN1212150C (zh) | 治疗病毒性肝炎的药物及制备方法 | |
CN1207002C (zh) | 一种抗肿瘤组合物及其制备方法和用途 | |
CN1872243A (zh) | 护肝降脂软胶囊及其用葡萄皮和葡萄籽制备葡萄护肝降脂软胶囊生产方法 | |
CN1308017C (zh) | 一种治疗泻泄、痢疾和痧气的药物组合物 | |
CN101062083A (zh) | 雷公藤减毒炮制方法及相关制剂 | |
CN101062108A (zh) | 一种治疗痛经的药物组合物及其制备方法 | |
CN1490014A (zh) | 芒果总甙制剂及其生产方法 | |
CN1919244A (zh) | 一种治疗心血管疾病的中药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU ZHENGDA TIANQING PHARMACEUTICAL CO., LTD. Effective date: 20111207 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20111207 Address after: Nanjing City, Jiangsu Province, Tong Lane 210009 No. 24 Co-patentee after: Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. Patentee after: China Pharmaceutical University Address before: Nanjing City, Jiangsu Province, Tong Lane 210009 No. 24 Patentee before: China Pharmaceutical University |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: Nanjing City, Jiangsu Province, Tong Lane 210009 No. 24 Patentee after: China Pharmaceutical University Patentee after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Address before: Nanjing City, Jiangsu Province, Tong Lane 210009 No. 24 Patentee before: China Pharmaceutical University Patentee before: Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070808 Termination date: 20180629 |
|
CF01 | Termination of patent right due to non-payment of annual fee |